A phase 3 trial is evaluating ASP-1929 photoimmunotherapy plus Keytruda in first-line treatment for recurrent head and neck ...

John Friend, MD, CEO of Kazia Therapeutics added, "The novelty of the science that Professor Rao has proposed with this dual ...

The LEAP-015 study is evaluating Merck's Keytruda and Eisai's Lenvima plus chemotherapy in certain types of gastroesophageal ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Last year wasn't a good one for Merck (NYSE: MRK), one of the largest pharmaceutical companies in the world. The healthcare ...

Co., Inc. (NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in pulmonary arterial ...

Results have been announced from a Phase III trial of Merck & Co’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bispecifics ...

Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete ...

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...

Merck (MRK) and Esai (ESALF) (ESAIY) announce a mixed outcome in their Phase 3 LEAP-015 trial for Keytruda/ Lenvima regimen ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...